Losartan: Side Effects and Contraindications

Losartan is one of the most widely prescribed blood pressure medicines in the UK, and it increasingly comes up in conversations about protecting the heart and kidneys of people who train hard. It is, however, a prescription-only medicine with a well-defined list of side effects and situations where it must not be used. Our editorial team has summarised what the licensing documents and the major trials actually say.
What losartan is and why it is prescribed
Losartan belongs to the angiotensin II receptor blockers, often shortened to ARBs or "sartans". It blocks the AT1 receptor, through which angiotensin II narrows blood vessels and prompts the adrenal glands to release aldosterone. With that signal dampened, vessels relax, blood pressure falls and the kidneys retain less salt and water.
In the UK it is licensed for essential hypertension, for protecting the kidneys in people with type 2 diabetes and protein in the urine, and for chronic heart failure when an ACE inhibitor is not tolerated. NICE guidance places ARBs alongside ACE inhibitors as first-line options for many adults with raised blood pressure.
The licensed dose range in the product information is 25–100 mg once daily, chosen by the prescriber according to the condition, kidney function and response. We quote this only as a labelling fact: the dose is a medical decision, not something to copy from a forum or adjust on your own.
Two landmark trials shaped its reputation. LIFE compared losartan with atenolol in hypertensive patients with left ventricular hypertrophy, and RENAAL tested it in diabetic nephropathy. Both reported meaningful benefits on hard outcomes, which is why "organ protection" is so often mentioned in connection with this drug.
Common and serious side effects
Most people tolerate losartan well, and in trials the overall rate of side effects was close to placebo. The effects that do appear follow logically from how the drug works: lower blood pressure, altered kidney blood flow and reduced aldosterone, which changes how the body handles potassium.
| Effect | How often (per labelling) | What it looks like |
|---|---|---|
| Dizziness, light-headedness | Common | Especially when standing up quickly or after the first doses |
| Low blood pressure | Common in dehydrated or salt-depleted people | Faintness, blurred vision, fatigue |
| Raised potassium (hyperkalaemia) | Common in kidney disease | Often silent; in severe cases muscle weakness or palpitations |
| Reduced kidney function | Uncommon to common depending on risk | Rising creatinine on blood tests |
| Angioedema | Rare | Swelling of lips, tongue or throat – an emergency |
A dry cough, the classic nuisance of ACE inhibitors, is much less frequent with ARBs because they do not block the breakdown of bradykinin. This is one of the main reasons doctors switch patients from ramipril or lisinopril to losartan.
Angioedema is rare but potentially life-threatening. Anyone who develops swelling of the face, tongue or throat, or difficulty breathing, should call 999. The risk is higher in people who have had angioedema with an ACE inhibitor before.
Less specific complaints such as tiredness, back pain or upset stomach are reported, although in controlled studies many occurred at similar rates on placebo. A clear change in how you feel after starting the tablet is still worth mentioning to the prescriber.

Contraindications: when losartan must not be used
The product information lists a short but firm set of contraindications. These are not matters of preference; they reflect situations in which the potential for harm clearly outweighs any benefit.
- Pregnancy, particularly the second and third trimesters: drugs acting on the renin–angiotensin system can damage fetal kidneys and skull development. The MHRA advises that they should be stopped as soon as pregnancy is confirmed.
- Known hypersensitivity to losartan or any excipient.
- Severe hepatic impairment, because the drug and its active metabolite are processed by the liver.
- Combination with aliskiren in people with diabetes or reduced kidney function (eGFR below 60 ml/min/1.73 m²).
Beyond the formal list there are cautions: narrowing of the arteries to both kidneys, primary hyperaldosteronism, aortic or mitral valve stenosis and hypertrophic cardiomyopathy. In these conditions the drug may still be used, but only with specialist judgement and closer monitoring.
Women who could become pregnant are usually counselled about contraception and about switching treatment before trying to conceive. Breastfeeding is another area where alternatives with more data are generally preferred.
Dual blockade, meaning losartan combined with an ACE inhibitor, is no longer recommended for most patients. Trials of such combinations showed more kidney injury and hyperkalaemia without a clear gain in outcomes.
Interactions that matter for active people
The interaction that worries pharmacists most is the so-called "triple whammy": an ARB or ACE inhibitor, a diuretic and an NSAID such as ibuprofen or naproxen taken together. A large UK case-control study published in the BMJ linked this combination to a higher risk of acute kidney injury, especially in the first weeks of use.
For people who train, this is very practical. Ibuprofen for a sore knee, a hot session, heavy sweating and a missed drink can push kidney blood flow down at exactly the wrong moment. Paracetamol is usually a safer first choice for pain, but check with your pharmacist.
Potassium is the second issue. Potassium supplements, salt substitutes based on potassium chloride, potassium-sparing diuretics and trimethoprim all add to the potassium-retaining effect of losartan. Some "electrolyte" drinks contain more potassium than people expect.
Lithium levels can rise when combined with losartan, and some herbal products may lower or raise blood pressure unpredictably. Always tell the prescriber about supplements, including those bought in sports shops.
Losartan, sport and monitoring
Losartan is not on the WADA Prohibited List, so its prescribed use does not create an anti-doping issue. Interest from athletes, however, sometimes goes beyond medical treatment, for example in the hope of protecting the heart during heavy training or substance use. There is no good evidence to support self-prescription for this purpose.
Blood tests are part of normal care. Most prescribers check kidney function and potassium before starting, again after one to two weeks and after any dose change, then periodically. Intense exercise can raise creatinine temporarily, so it helps to avoid hard sessions for a day or two before the test.
A home blood pressure monitor is useful for anyone on treatment. Readings that are consistently low, or dizziness during training, are reasons to speak to the GP rather than to skip tablets on training days.
During illness with vomiting, diarrhoea or fever, NHS "sick day rules" may advise temporarily pausing ARBs to protect the kidneys. This should be agreed with a clinician in advance rather than improvised.
Conclusions of the editorial team
Losartan is an established, generally well tolerated medicine with proven benefits in hypertension, diabetic kidney disease and heart failure. Its side effects are predictable: dizziness, low blood pressure, raised potassium and changes in kidney function.
The firm contraindications are pregnancy, hypersensitivity, severe liver disease and combination with aliskiren in at-risk patients. For active people, the biggest practical hazards are NSAIDs, dehydration and hidden potassium.
Losartan should only be taken on prescription, with the blood tests the prescriber arranges.
If you found this useful, you may also want to read our pieces on reading a kidney function panel, on why ibuprofen and endurance events are a risky mix, and on how to measure blood pressure correctly at home.
References
- Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
- Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: the ELITE II trial. Lancet. 2000;355(9215):1582–1587.
- Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.
- National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management (NG136). London: NICE; 2019.
- ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.


